Qingdao Vland Biotech INC. (SHA:603739)

Market Cap	3.73B -0.9%
Revenue (ttm)	1.40B +4.2%
Net Income	78.10M +31.3%
EPS	0.31 +27.9%
Shares Out	253.03M
PE Ratio	47.83
Forward PE	42.14
Dividend	0.10 (0.65%)
Ex-Dividend Date	May 30, 2025

Volume	4,282,500
Average Volume	3,989,347
Open	15.25
Previous Close	15.28
Day's Range	14.70 - 15.26
52-Week Range	12.63 - 18.41
Beta	0.48
RSI	45.50
Earnings Date	Apr 25, 2026

About SHA:603739

Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological products, such as live and inactivated, and poultry and swine vaccines, as well as egg yolk antibodies; poultry drugs comprising anti-parastic, antivir...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 1,535
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603739

Financial Performance

In 2025, SHA:603739's revenue was 1.37 billion, an increase of 3.43% compared to the previous year's 1.32 billion. Earnings were 69.81 million, an increase of 11.45%.